CordenPharma Acquires AmbioPharm to Expand Global Peptide API Capacity
PR Newswire
BASEL, Switzerland, May 27, 2026
Acquisition strengthens U.S. peptide manufacturing capabilities and broadens global expertise in complex peptide APIsCordenPharma has entered into an agreement to acquire AmbioPharm, a U.S.-headquartered peptide CDMO with facilities in North Augusta, South Carolina (USA) and Shanghai (China). With the acquisition, CordenPharma broadens its peptide API development and manufacturing capabilities for complex peptide programs.The transaction expands CordenPharma's upstream and downstream peptide manufacturing footprint by adding further capacity for U.S.-based peptide API supply and bringing Shanghai-based production options into its network for global customers. The deal bolsters CordenPharma's peptide CDMO capabilities, giving customers broader choices in manufacturing lines, scale-up path and regional / global supply models.BASEL, Switzerland, May 27, 2026 /PRNewswire/ -- CordenPharma, a leading global Contract Development and Manufacturing Organization (CDMO), today announces that it has entered into an agreement to acquire AmbioPharm, a U.S.-headquartered peptide API CDMO.
